scholarly journals Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Norbert Pardi ◽  
Kaela Parkhouse ◽  
Ericka Kirkpatrick ◽  
Meagan McMahon ◽  
Seth J. Zost ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Specific Antibodies ◽  
Influenza Virus Hemagglutinin

scholarly journals Swainsonine prevents the processing of the oligosaccharide chains of influenza virus hemagglutinin.

1982 ◽  
Vol 257 (4) ◽  
pp. 1573-1576 ◽  
Author(s):  
A.D. Elbein ◽  
P.R. Dorling ◽  
K. Vosbeck ◽  
M. Horisberger
Keyword(s):  
Influenza Virus ◽  
Influenza Virus Hemagglutinin

scholarly journals A Novel Gene Delivery Vector of Agonistic Anti-Radioprotective 105 Expressed on Cell Membranes Shows Adjuvant Effect for DNA Immunization Against Influenza

2020 ◽  
Vol 11 ◽  
Author(s):  
Tatsuya Yamazaki ◽  
Mrityunjoy Biswas ◽  
Kouyu Kosugi ◽  
Maria Nagashima ◽  
Masanori Inui ◽  
...  
Keyword(s):  
Influenza Virus ◽  
B Cells ◽  
Intracellular Signaling ◽  
Transmembrane Domain ◽  
Lethal Dose ◽  
Influenza Virus Infection ◽  
Target Antigen ◽  
Dna Immunization ◽  
Adjuvant Effect ◽  
Specific Antibodies

Radioprotective 105 (RP105) (also termed CD180) is an orphan and unconventional Toll-like receptor (TLR) that lacks an intracellular signaling domain. The agonistic anti-RP105 monoclonal antibody (mAb) can cross-link RP105 on B cells, resulting in the proliferation and activation of B cells. Anti-RP105 mAb also has a potent adjuvant effect, providing higher levels of antigen-specific antibodies compared to alum. However, adjuvanticity is required for the covalent link between anti-RP105 mAb and the antigen. This is a possible obstacle to immunization due to the link between anti-RP105 mAb and some antigens, especially multi-transmembrane proteins. We have previously succeeded in inducing rapid and potent recombinant mAbs in mice using antibody gene-based delivery. To simplify the covalent link between anti-RP105 mAb and antigens, we generated genetic constructs of recombinant anti-RP105 mAb (αRP105) bound to the transmembrane domain of the IgG-B cell receptor (TM) (αRP105-TM), which could enable the anti-RP105 mAb to link the antigen via the cell membrane. We confirmed the expression of αRP105-TM and the antigen hemagglutinin, which is a membrane protein of the influenza virus, on the same cell. We also found that αRP105-TM could activate splenic B cells, including both mature and immature cells, depending on the cell surface RP105 in vitro. To evaluate the adjuvanticity of αRP105-TM, we conducted DNA immunization in mice with the plasmids encoding αRP105-TM and hemagglutinin, followed by challenge with an infection of a lethal dose of an influenza virus. We then obtained partially but significantly hemagglutinin-specific antibodies and observed protective effects against a lethal dose of influenza virus infection. The current αRP105-TM might provide adjuvanticity for a vaccine via a simple preparation of the expression plasmids encoding αRP105-TM and of that encoding the target antigen.

Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites

1985 ◽  
Vol 22 (2) ◽  
pp. 145-154 ◽  
Author(s):  
Ann Nestorowicz ◽  
Geoffrey W. Tregear ◽  
Christina N. Southwell ◽  
John Martyn ◽  
Julie M. Murray ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Synthetic Peptides ◽  
Antigenic Sites ◽  
Influenza Virus Hemagglutinin
Sign in / Sign up

Export Citation Format

Share Document